

Onconova Therapeutics Investor Relations Department 375 Pheasant Run Newtown, PA 18940 United States

Visit IR website ☐ Sign-up for Email alerts ☐


NASDAQ: ONTX	
Last Trade:	1.60
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	0.04 👚 (+2.564%)
Day Range	1.53 - 1.60
52-Week Range	1.53 - 4.10
Volume	16,298

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova's lead compound, rigosertib, are aimed at un... (more)

Stock Performance



Press Releases [View all]

Aug 15, 2017

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results

Aug 8, 2017

Onconova Therapeutics, Inc. to Provide
Corporate Update and Second Quarter 2017
Financial Results

Jul 25, 2017

Onconova Therapeutics Announces

<u>Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric "RASopathies"</u>

Jun 26, 2017

Onconova Therapeutics Presents Rigosertib

Data at the 22nd Congress of the European

Hematology Association in Madrid

Jun 13, 2017

Onconova Therapeutics to Present at the BIO International Convention

Financials [View all]

Second Quarter Financial Results

Mar 29, 2017

Annual Report (10-K)

Apr 12, 2017

Proxy Statement (DEF 14A)

Aug 14, 2017

Quarterly Report (10-Q)

May 15, 2017

Quarterly Report (10-Q)

Nov 14, 2016

Quarterly Report (10-Q)